Identification of LZTR1 leads to novel insights into RAS-driven diseases

(VIB (the Flanders Institute for Biotechnology)) Mutations in RAS proteins initiate many of the most aggressive tumors, and the search for pharmacological inhibitors of these proteins has become a priority in the battle against cancer. Michail Steklov, Francesca Baietti, and colleagues from the Anna Sablina lab (VIB-KU Leuven Center for Cancer Biology) identified LZTR1 as an evolutionarily conserved component of the RAS pathway.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news